Your browser doesn't support javascript.
loading
Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer.
Farahmand, Saman; Fernandez, Aileen I; Ahmed, Fahad Shabbir; Rimm, David L; Chuang, Jeffrey H; Reisenbichler, Emily; Zarringhalam, Kourosh.
Afiliação
  • Farahmand S; University of Massachusetts-Boston, Department of Mathematics, Boston, MA, USA.
  • Fernandez AI; University of Massachusetts-Boston, Computational Sciences PhD Program, Boston, MA, USA.
  • Ahmed FS; Yale University, Yale School of Medicine, Department of Pathology, New Haven, CT, USA.
  • Rimm DL; Yale University, Yale School of Medicine, Department of Pathology, New Haven, CT, USA.
  • Chuang JH; Yale University, Yale School of Medicine, Department of Pathology, New Haven, CT, USA.
  • Reisenbichler E; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA. Jeff.Chuang@jax.org.
  • Zarringhalam K; UCONN Health, Department of Genetics and Genome Sciences, Farmington, CT, USA. Jeff.Chuang@jax.org.
Mod Pathol ; 35(1): 44-51, 2022 01.
Article em En | MEDLINE | ID: mdl-34493825

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Trastuzumab / Antineoplásicos Imunológicos Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Mod Pathol Assunto da revista: PATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Trastuzumab / Antineoplásicos Imunológicos Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Mod Pathol Assunto da revista: PATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos